ClinicalTrials.gg
Not yet recruitingNCT07475988IDEAS-AUDUpdated Mar 17, 2026

Adapting a Telehealth Intervention for Suicide Prevention Among Patients With Alcohol Use Disorder in Tanzania

An interventional study of IDEAS-AUD in Alcohol Use Disorder and Suicide Prevention, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Duke University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Together, alcohol use and suicide account for approximately 4 million deaths per year, with a considerable burden on low and middle-income countries. Tanzania is among the world's most underserved nations for mental health treatment, with very little capacity to treat suicidality or alcohol use disorders. In this study, the researchers will adapt an evidence-based intervention for suicide prevention to address the unique needs of people with alcohol use disorders in Tanzania, and rigorously pilot test the intervention to assess its feasibility and acceptability in a Tanzanian emergency department.

Read the detailed description

Globally, alcohol use disorders (AUD) cause 3.3 million deaths each year and account for nearly 100 million disability-adjusted life years (DALYs). Alcohol use is also one of the most prominent risk factors for death by suicide, as people with AUD have a lifetime risk of suicide more than 7 times higher than the general population. In preliminary studies at Kilimanjaro Christian Medical Centre (KCMC) in Tanzania, 7% of patients with AUD met criteria for comorbid depression, 7% were experiencing suicidal thoughts or behavior, and nearly half reported challenges in social support. Unfortunately, Tanzania is also among the most underserved nations in the world for mental health treatment, with fewer than 1 psychologist or psychiatrist per 1 million people and very little capacity to intervene for suicide risk or AUD. Given this shortage in treatment, there is a critical need for innovative, resource-efficient treatments for suicide prevention among people with AUD. In Tanzania, 91% of the population owns a cellular phone and nearly 50% use mobile internet, yet telehealth interventions have been largely unexplored, representing a major missed opportunity for delivering evidence-based interventions. By adapting an evidence-based Motivational Interviewing intervention, MI-SafeCope, the team developed IDEAS for Hope, a telehealth intervention for suicide prevention in HIV care in Tanzania. In the current grant, the researchers propose to revisit this process by adapting MI-SafeCope, with lessons learned from the HIV study, to reduce suicide risk among people with AUD who are presenting for care in the KCMC Emergency Department (ED). The resulting intervention, IDEAS-AUD, will address suicide risk with a four-pillared approach: reducing alcohol-related harm, building social support, enhancing emotional health, and addressing social determinants of health. The pillars are integrated with Motivational Interviewing-enhanced safety planning and referral for local psychiatric care as appropriate. The long-term goal is to create evidence-based, accessible, and cost-effective treatments for mental health and substance use treatment in low-resource settings. The objectives of this proposal are to: 1) adapt IDEAS-AUD for the AUD population in Kilimanjaro, Tanzania; 2) rigorously evaluate the acceptability and feasibility of IDEAS-AUD; and 3) develop the intervention package, along with a trialability evaluation, for a future implementation evaluation and clinical trial. In Aim 1 of the current study, the researchers will identify drivers of suicide risk and desired intervention characteristics to prevent suicide in the AUD population at KCMC. In Aim 2, the study team will adapt an evidence-based suicide prevention intervention to existing AUD care, guided by a community coalition. In Aim 3, the investigators will pilot test the telehealth intervention to assess its feasibility and acceptability for reducing suicide risk in the KCMC AUD population. By the end of this proposed project, the researchers will have a framework-guided, culturally- and resource-adapted, piloted protocol for IDEAS-AUD, including screening tools, programmatic, and implementation components.

02

Conditions studied

  • Alcohol Use Disorder
  • Suicide Prevention

Keywords

  • Telehealth
  • Nurse-delivered interventions
  • Stigma reduction
  • Care engagement
  • Suicide prevention
  • Health behavior
  • Alcohol use disorder
  • Harm reduction
03

In context

Alcoholism

1,674 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

This study's planned enrollment of 30 is below the median of 88 across 1,428 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • screen positive for alcohol use disorder (AUDIT >=8)
  • have had suicidal thinking (C-SSRS item indicating "actual thoughts of suicide") in last 30 days
  • clinically sober
  • medically stable
  • have the physical and cognitive capacity to provide consent and complete study procedures
  • able to communicate in Swahili or English

Exclusion criteria

Exclusion Criteria:

  • prisoners
  • decline or unable to complete
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    IDEAS-AUD

    3 sessions of telehealth-delivered counseling

    Behavioral: IDEAS-AUD

Interventions

  • BehavioralIDEAS-AUD

    Telehealth-delivered counseling to reduce suicide risk among people with Alcohol Use Disorder (AUD) who are presenting for care in the KCMC Emergency Department (ED).

06

What researchers measure

Primary outcomes

  1. Acceptability of intervention

    Acceptability of Intervention Measure (AIM). Four items scored from 1-Completely disagree to 5-Completely agree. Scores are summed for a total score of 4 to 20, with higher scores indicating greater acceptability.

    Time frame: 3 months

  2. Enrollment feasibility as measured by the percentage of ED patients with documented screening for study eligibility

    Time frame: up to 1 year

  3. Enrollment feasibility as measured by the number of eligible participants who declined enrollment

    Time frame: up to 1 year

  4. Enrollment feasibility as measured by the time needed to enroll 30 eligible participants

    Time frame: up to 1 year

  5. Retention feasibility as measured by the number of participants retained for follow-up

    Time frame: session 2 (2 weeks), session 3 (4 weeks), and 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2027; primary completion for Mar 2029, 19 months later.

Of 470 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 19 months is below that.

Counting every sponsor, half of 493 studies reached it within 33 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Aug 2027
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475988
Lead sponsor
Duke University
Collaborators
Kilimanjaro Christian Medical Centre, Tanzania
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Aug 2027 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Mar 17, 2026

Study contacts

Brandon Knettel, PhD
Contact
brandon.knettel@duke.edu
9196601218
Brandon Knettel, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion